Good evening :)
Place Order
Add to Watchlist

Marksans Pharma Ltd

MARKSANS

Marksans Pharma Ltd

MARKSANS
Health CarePharmaceuticals
SmallcapWith a market cap of ₹7,062 cr, stock is ranked 580
High RiskStock is 4.57x as volatile as Nifty
176.7013.38% (+20.85)
176.7013.38% (+20.85)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Health CarePharmaceuticals
SmallcapWith a market cap of ₹7,062 cr, stock is ranked 580
High RiskStock is 4.57x as volatile as Nifty

How to use scorecard? Learn more

Health CarePharmaceuticals
SmallcapWith a market cap of ₹7,062 cr, stock is ranked 580
High RiskStock is 4.57x as volatile as Nifty

Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
22.264.000.32%
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
51.555.890.57%

Forecast & Ratings

Detailed Forecast 
Forecast data is currently unavailable for this stock

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Marksans Pharma Limited is a pharmaceutical company, which is engaged in the research, manufacturing and marketing of generic pharmaceutical formulations.

Investor Presentation

View older 

Aug 11, 2023

PDF
View Older Presentations

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

Forecasts

Price

Revenue

Earnings

Income

Balance Sheet

Cash Flow

Income Statement

Industry refers to the sub-sector this company belongs to.

Higher than Industry Revenue Growth

A higher-than-industry revenue growth represents increased potential for the company to increase their market share

Over the last 5 years, revenue has grown at a yearly rate of 15.72%, vs industry avg of 8.36%

Increasing Market Share

Market share is the percentage of an industry's total sales going to a particular company. It gives a general idea of the size of a company v/s its competitors

Over the last 5 years, market share increased from 0.45% to 0.59%

Higher than Industry Net Income

Net income is equal to net earnings (profit) less expenses. This number is an important measure of how profitable the company is

Over the last 5 years, net income has grown at a yearly rate of 51.9%, vs industry avg of 9.82%

Loading...

Financial YearFY 2015FY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023TTM
Total Revenue800.03902.20774.18921.161,004.691,134.541,382.871,532.691,911.452,148.28
Raw Materialssubtract446.74504.85506.68502.58517.91514.88731.33703.92927.751,644.90
Power & Fuel Costsubtract9.7212.5812.9711.5513.9914.0015.9518.5924.50
Employee Costsubtract72.61122.42149.70147.75159.07168.42197.32220.30239.37
Selling & Administrative Expensessubtract49.8265.7865.1888.83109.58120.38154.55189.98144.74
Operating & Other expensessubtract33.0851.43-12.1283.6067.38124.28-62.5899.17176.46
Depreciation/Amortizationsubtract16.1328.1330.0926.8422.8026.6636.1544.7851.8567.15
Interest & Other Itemssubtract16.0510.166.7810.229.668.757.998.459.138.81
Taxes & Other Itemssubtract46.4928.336.0616.8627.8436.4263.6262.9571.34110.08
EPS2.751.920.220.801.872.955.834.516.187.00
DPS0.120.410.050.050.050.100.250.250.500.50
Payout ratio0.040.210.230.060.030.030.040.060.080.07

Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2021

Annual report

PDF

Investor Presentation

May 31PDF
FY 2022

Annual report

PDF

Investor Presentation

May 30PDF
Feb 11PDF
Nov 10PDF
Aug 11PDF
FY 2023

Annual report

PDF

Investor Presentation

May 30PDF
Feb 13PDF
Nov 14PDF
Aug 13PDF
FY 2024

Annual Report Pending

Investor Presentation

Aug 11PDF
 

Peers & Comparison

Comparing 3 stocks from 
Health CarePharmaceuticals

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Marksans Pharma Ltd26.524.000.32%
Sun Pharmaceutical Industries Ltd43.616.230.75%
Cipla Ltd39.804.700.62%
Dr Reddy's Laboratories Ltd22.214.300.67%

Price Comparison

Compare MARKSANS with any stock or ETF
Compare MARKSANS with any stock or ETF
MARKSANS
Loading...

Shareholdings

Promoter Holdings Trend

Total Promoter Holding

Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding

Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Institutional Holdings Trend

Decreased Total Retail Holding

Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has decreased by 1.30%

Foreign Institutional Holding

Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding43.85%3.82%0.94%15.56%35.83%

Mar 2023

Jun 2023

Sep 2023

Dec 2023

Shareholding History

Dec '22JanMarJunSepDec '234.24%14.83%15.12%14.91%15.07%15.56%

Mutual Funds Holding Trend

Mutual Fund Holding

Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has almost stayed constant

Top 5 Mutual Funds holding Marksans Pharma Ltd




Funds (Top 5)Market-cap heldWeight3M holding changePortfolio rank
(3M change)
Quant Small Cap Fund - Growth - Direct Plan

Growth
2.6944%1.11%-0.46%33/123 (-5)
UTI Aggressive Hybrid Fund - Growth - Direct Plan

Growth
0.5291%0.71%0.07%73/118 (-6)
UTI Large & Mid Cap Fund - Growth - Direct Plan

Growth
0.2672%0.71%-0.02%67/72 (-22)

Compare 3-month MF holding change on Screener

Insider Trades & Bulk Deals

Loading...

smallcases

Looks like this stock is not in any smallcase yet.

Events

Dividend Trend

No Dividend Cuts

Dividends are the portion of earnings that a company distributes to all its shareholders every year

MARKSANS has increased or maintained dividend levels over the last 5 years

Dividend Yield

Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation

Current dividend yield is 0.31%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹3.06 every year

Dividends

Corp. Actions

Announcements

Legal Orders

Upcoming Dividends

No upcoming dividends are available

Past Dividends

Cash Dividend

Ex DateEx DateJun 7, 2023

Final
Final | Div/Share: ₹0.50

Dividend/Share

0.50

Ex DateEx Date

Jun 7, 2023

Cash Dividend

Ex DateEx DateAug 19, 2022

Final
Final | Div/Share: ₹0.25

Dividend/Share

0.25

Ex DateEx Date

Aug 19, 2022

Cash Dividend

Ex DateEx DateSep 15, 2021

Final
Final | Div/Share: ₹0.25

Dividend/Share

0.25

Ex DateEx Date

Sep 15, 2021

Cash Dividend

Ex DateEx DateSep 22, 2020

Final
Final | Div/Share: ₹0.10

Dividend/Share

0.10

Ex DateEx Date

Sep 22, 2020

Cash Dividend

Ex DateEx DateSep 19, 2019

Final
Final | Div/Share: ₹0.05

Dividend/Share

0.05

Ex DateEx Date

Sep 19, 2019